Korea To Introduce Fast-Track Review For Cutting-Edge Biologics, Devices
Executive Summary
South Korea is set to adopt fast-track review systems for cutting-edge biologics and medical devices late this year as it continues to nurture the biotech industry and in line with global trends
You may also be interested in...
What Can Korea Learn From The Invossa Trial And Error Case?
South Korea, which has recently delayed the political passage of a cutting-edge regenerative medicine and biologics act, should learn from the latest unprecedented incident involving Kolon Life Science’s cell and gene therapy Invossa, and pre-emptively make preparations and guidelines to better deal with such pioneering medicines, an industry expert tells Scrip.
Korea Seeks Fast Tracks For Innovative And Public Health Crisis Drugs
Korean pharma industry welcomes a bill that aims to establish fast-track review and approval system for innovative drugs and medicines used in public health crises.
Korea To Bolster Fast-Track System With Speedier Drug Approvals In Mind
South Korea plans to draw up detailed guidelines for a fast-track drug review and approval system this year to increase applications for such reviews, provide the pharma industry with a clearer understanding of the process, and provide timely patient access to more treatment options.